

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 31/00, 31/69, 38/55, A61P 37/00, 37/08, 29/00, 35/00, 1/00, 9/10, 31/00, 31/12, 43/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/10549</b> <b>(43) International Publication Date:</b> 2 March 2000 (02.03.00)
<b>(21) International Application Number:</b> PCT/US99/18315 <b>(22) International Filing Date:</b> 13 August 1999 (13.08.99) <b>(30) Priority Data:</b> 60/097,376 21 August 1998 (21.08.98) US <b>(71) Applicant (for all designated States except US):</b> POINT THERAPEUTICS, INC. [US/US]; 75 Kneeland Street, Boston, MA 02111 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> WALLNER, Barbara [-/US]; 64 Arrowhead Road, Weston, MA 02193 (US). <b>(74) Agent:</b> GOSZ, William, G.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> REGULATION OF SUBSTRATE ACTIVITY		
<b>(57) Abstract</b>  A method for regulating substrate activity <i>in vivo</i> is useful for the treatment of medical disorders such as inflammation, arteriolosclerosis and angiogenesis. The method involves the administration of an effective amount of a DPP-IV inhibitor to a patient in need of such treatment.		